Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

Journal of Neuro-Oncology

Volumn 89, Issue 2, 2008, Pages 179-185

  Tosoni, A ^a   Franceschi, E ^a   Ermani, M ^b   Bertorelle, R ^c   Bonaldi, L ^c   Blatt, V ^b   Brandes, Alba A ^a  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

1p 19q deletions; Clinical trials; Low grade gliomas; MGMT; Prolonged temozolomide

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METOCLOPRAMIDE; SEROTONIN ANTAGONIST; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENE DELETION; GLIOMA; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OLIGODENDROGLIOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PROTEIN METHYLATION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR RECURRENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 48749129565     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9600-y     Document Type: Article

References (22)

1. CBTRUS, C.B.t.r.o.t.U.S. (2004) Primary brain tumors in the United States. Statistical report 1997-2001
2. Brandes AA, Tosoni A, Kortmann RD (2003) Guidelines for the management and treatment of low-grade gliomas. Forum (Genova) 13:4-17
3. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051
4. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011
5. Denis L, Tolcher A, Figueroa et al (2000) Protracted daily administration of temozolomide is feasible: A phase I and pharmacokinetic - pharmacodynamic study. In ASCO Proceedings, 2000 Annual Meeting, abstract number 786
6. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160
7. Tosoni A, Cavallo G, Ermani M et al (2006) Is protracted low-dose temozolomide feasible in glioma patients? Neurology 66:427-429
8. Kovacs JA, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342:1416-1429
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
10. Kaplan E, Meier P (1958) Non parametric estimation for incomplete observation. J Am Stat Assoc 53:457-481
11. Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954-5958
12. van Engeland M, Weijenberg MP, Roemen GMJM et al (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: The Netherlands cohort study on diet and cancer. Cancer Res 63:3133-3137
13. Simon R (1989) Designs for efficient clinical trials. Oncology (Huntingt) 3:43-49 discussion 51-43
14. Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721
15. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138
16. Pace A, Vidiri A, Galie E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 14:1722-1726
17. Hoang-Xuan K, He J, Huguet S, Mokhtari K et al (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278-1281
18. Quinn JA, Reardon DA, Friedman AH et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651
19. Mariani L, Deiana G, Vassella E et al (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758-4763
20. Kujas M, Lejeune J, Benouaich-Amiel A et al (2005) Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322-326
21. Everhard S, Kaloshi G, Criniere E et al (2006) MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743
22. 6 -methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176-184